The NYT continues its excellent coverage of abuses in the prescription drug industry. It pointed out that several doctors questioned whether a new study by GlaxoSmithKline, that was supposed to demonstrate the safety of one its diabetes drugs, in fact showed that the study was safe.
It's great that the NYT has devoted so much of its resources to uncovering efforts by the drug industry to mislead the public about the safety and effectiveness of its drugs. However, it would be even better if it devoted attention to the nature of the patent system that provides such enormous incentives for such abuses. There are alternative methods for financing prescription drug development. Until we adopt an alternative model, we can expect to see many more pieces exposing the abuses of the current one.
Unlike many news organizations, the Prospect has remained staunchly committed to keeping our journalism free and accessible to all. We believe that independent journalism is crucial for a functioning democracy—but quality reporting comes at a cost.
This year, we’re aiming to raise $75,000 to continue delivering the hard-hitting investigative journalism you’ve come to expect from us. Your support helps us maintain our independence and dig deeper into the stories that matter most.
If you value our reporting, please consider making a contribution today. Any amount helps secure our future and ensure we can continue holding power to account.
